Cassaday & Co Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.32M Buy
5,464
+96
+2% +$113K 0.11% 42
2026
Q2
$6.44M Sell
5,368
-40
-0.7% -$40.9K 0.12% 41
2026
Q1
$4.97M Sell
5,408
-142
-3% -$144K 0.11% 44
2025
Q4
$5.96M Sell
5,550
-352
-6% -$337K 0.13% 41
2025
Q3
$4.5M Buy
5,902
+158
+3% +$118K 0.1% 51
2025
Q2
$4.48M Buy
5,744
+195
+4% +$152K 0.11% 47
2025
Q1
$4.58M Sell
5,549
-66
-1% -$54.9K 0.13% 40
2024
Q4
$4.33M Buy
5,615
+45
+0.8% +$37.3K 0.12% 42
2024
Q3
$4.94M Buy
5,570
+113
+2% +$102K 0.14% 34
2024
Q2
$4.94M Buy
5,457
+12
+0.2% +$9.6K 0.16% 34
2024
Q1
$4.24M Buy
5,445
+827
+18% +$589K 0.14% 37
2023
Q4
$2.69M Hold
4,618
– – 0.09% 46
2023
Q3
$2.48M Buy
4,618
+18
+0.4% +$9.28K 0.1% 47
2023
Q2
$2.16M Sell
4,600
-186
-4% -$78K 0.09% 51
2023
Q1
$1.64M Buy
4,786
+400
+9% +$135K 0.07% 61
2022
Q4
$1.6M Buy
+4,386
New +$1.56M 0.07% 62

Other funds holding LLY

Cassaday & Co Wealth Management's LLY Position: Q3 2026 in Review

Cassaday & Co Wealth Management increased its Eli Lilly (LLY) stake by 1.8% in Q3 2026, buying an estimated $113K and bringing the position to 5,464 shares worth $6.32M. The position accounts for 0.11% of the portfolio, ranked #42.

Cassaday & Co Wealth Management first reported a position in LLY in Q4 2022 and has held it in 16 quarters since. The position peaked at $6.44M in Q2 2026. 3,177 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Cassaday & Co Wealth Management held 5,464 shares of Eli Lilly worth $6.32M as of Q3 2026.
  • Cassaday & Co Wealth Management bought 96 Eli Lilly shares in Q3 2026, an estimated $113K.
  • Eli Lilly made up 0.11% of Cassaday & Co Wealth Management's portfolio in Q3 2026, its #42 holding.
  • Cassaday & Co Wealth Management first reported a position in Eli Lilly in Q4 2022 and has held it in 16 quarters since.
  • Cassaday & Co Wealth Management's Eli Lilly position peaked at $6.44M in Q2 2026.
  • 3,177 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q3 2026, filed 27 Oct 2026.